Clinical trial Phase 3 Interventional Ages 18 and up

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Run by Eli Lilly and Company · NCT06260722 · Data updated 2026-11-12

Fully enrolled, still running. This study is not taking new participants. Its registered completion date is 2026-08-27.

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.

Research outlook What's coming for Type 2 diabetes: the next 6 months to 5 years

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment1250 (estimated)
SponsorEli Lilly and Company
Industry-sponsored
Drugs / interventionsRetatrutide, Semaglutide
Locations77 sites (Argentina, Canada, Mexico, Puerto Rico, United States)
Trial IDNCT06260722 on ClinicalTrials.gov

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Have Type 2 Diabetes (T2D)
* Have HbA1c ≥ 7.0% (53 millimoles per mole (mmol/mol)) to ≤ 10.5% (91 mmol/mol)
* Have been on a stable diabetes treatment consisting of metformin ≥ 1500 milligrams per day (mg/day) with or without SGLT2i during 90 days prior to screening
* Are of stable weight for at least 90 days prior to screening
* Have a Body Mass Index (BMI) ≥ 25.0 kilograms per meter squared (kg/m\^2)

Exclusion Criteria:

* Have Type 1 Diabetes (T1D)
* Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening
* Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening
* Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
* Have an estimated glomerular filtration rate (eGFR) \<45 milliliters/minute/1.73 meter squared (mL/min/1.73 m\^2) or lower than the country-specific threshold for discontinuing metformin therapy per local label as determined by the central laboratory
* Have a prior or planned surgical treatment for obesity
* Have New York Heart Association Functional Classification IV congestive heart failure
* Have had an acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screening
* Have a known clinically significant gastric emptying abnormality
* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years
* Have any lifetime history of a suicide attempt
* Had chronic or acute pancreatitis
* Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2
* Have taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening.

Where it's running

  • University of Alabama - Department of Nutrition Sciences
    Birmingham, Alabama, United States
  • Neighborhood Healthcare Institute of Health
    Escondido, California, United States
  • Long Beach Research Institute
    Long Beach, California, United States
  • Valley Clinical Trials, Inc.
    Northridge, California, United States
  • Rancho Cucamonga Clinical Research
    Rancho Cucamonga, California, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado, United States
Show 44 more locations
  • Arrow Clinical Trials
    Daytona Beach, Florida, United States
  • New Age Medical Research Corporation
    Miami, Florida, United States
  • South Broward Research
    Miramar, Florida, United States
  • Clinical Research of Central Florida
    Winter Haven, Florida, United States
  • Herman Clinical Research
    Suwanee, Georgia, United States
  • North Georgia Clinical Research
    Woodstock, Georgia, United States
  • Pacific Diabetes & Endocrine Center
    Honolulu, Hawaii, United States
  • Rocky Mountain Clinical Research
    Idaho Falls, Idaho, United States
  • Deaconess Clinic - Gateway Health Center
    Newburgh, Indiana, United States
  • IMA Clinical Research Monroe - Armand
    Monroe, Louisiana, United States
  • MedStar Health Research Institute (MedStar Physician Based Research Network)
    Hyattsville, Maryland, United States
  • Brigham and Women's Hospital Diabetes Program
    Boston, Massachusetts, United States
  • NECCR PrimaCare Research
    Fall River, Massachusetts, United States
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
    Troy, Michigan, United States
  • Palm Research Center Tenaya
    Las Vegas, Nevada, United States
  • Palm Research Center Sunset
    Las Vegas, Nevada, United States
  • NYC Research INC
    Long Island City, New York, United States
  • Medication Management
    Greensboro, North Carolina, United States
  • Remington Davis Clinical Research
    Columbus, Ohio, United States
  • Alliance for Multispecialty Research, LLC
    Norman, Oklahoma, United States
  • Central States Research
    Tulsa, Oklahoma, United States
  • The Corvallis Clinic, P.C.
    Corvallis, Oregon, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas, United States
  • Valley Institute of Research - Fort Worth
    Fort Worth, Texas, United States
  • Juno Research
    Houston, Texas, United States
  • Southern Endocrinology Associates
    Mesquite, Texas, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas, United States
  • Texas Valley Clinical Research
    Weslaco, Texas, United States
  • Medrasa Clinical Research
    Wylie, Texas, United States
  • Central Washington Health Services Association d/b/a Confluence Health
    Wenatchee, Washington, United States
  • IMA Clinical Research West Virginia
    Morgantown, West Virginia, United States
  • CARE - Centro de Alergia y Enfermedades Respiratorias
    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
  • Stat Research S.A.
    Buenos Aires, Buenos Aires F.D., Argentina
  • Ciprec
    Buenos Aires, Buenos Aires F.D., Argentina
  • Centro Médico Viamonte
    Buenos Aires, Buenos Aires F.D., Argentina
  • Mautalen Salud e Investigación
    Buenos Aires, Buenos Aires F.D., Argentina
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
    Buenos Aires, Buenos Aires F.D., Argentina
  • Cemediab
    C.a.b.a., Buenos Aires F.D., Argentina
  • Instituto Centenario
    Caba, Buenos Aires F.D., Argentina
  • Centro Medico Privado San Vicente Diabetes
    Córdoba, Córdoba Province, Argentina
  • CIPADI - Centro Integral de Prevencion y Atencion en Diabetes
    Godoy Cruz, Mendoza Province, Argentina
  • Centro de Investigaciones Clínicas Baigorria
    Granadero Baigorria, Santa Fe Province, Argentina
  • Instituto de Investigaciones Clinicas Rosario
    Rosario, Santa Fe Province, Argentina

+27 more sites. See ClinicalTrials.gov for the full list.

Study contacts

  • Principal investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) — Eli Lilly and Company

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.